[HTML][HTML] Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis
M Duvic, MT Tetzlaff, P Gangar, AL Clos… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
M Duvic, MT Tetzlaff, P Gangar, AL Clos, D Sui, R Talpur
Journal of Clinical Oncology, 2015•ncbi.nlm.nih.govResults of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and
Lymphomatoid Papulosis - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC4737859
Other Formats PubReader PDF (1.5M) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
Lymphomatoid Papulosis - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC4737859
Other Formats PubReader PDF (1.5M) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
Abstract
Purpose
Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30+ receptors. This phase II open-label trial was conducted to evaluate safety and efficacy in CD30+ cutaneous T-cell lymphomas.
ncbi.nlm.nih.gov